Cytokinetics, Incorporated (CYTK)

Market Cap	5.09B
Revenue (ttm)	18.47M
Net Income (ttm)	-589.53M
Shares Out	118.41M
EPS (ttm)	-5.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,915,602
Open	44.06
Previous Close	43.63
Day's Range	42.68 - 44.44
52-Week Range	40.53 - 75.71
Beta	0.95
Analysts	Strong Buy
Price Target	82.00 (+90.74%)
Earnings Date	May 7, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle tropo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 498
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2024, Cytokinetics's revenue was $18.47 million, an increase of 145.34% compared to the previous year's $7.53 million. Losses were -$589.53 million, 12.0% more than in 2023.

Analyst Forecast

According to 17 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price forecast is $82.0, which is an increase of 90.74% from the latest price.

Price Target

$82.0

(90.74% upside)

Analyst Consensus: Strong Buy